Insulet (PODD)
(Delayed Data from NSDQ)
$167.25 USD
-0.02 (-0.01%)
Updated Apr 24, 2024 04:00 PM ET
After-Market: $167.18 -0.07 (-0.04%) 7:46 PM ET
3-Hold of 5 3
D Value A Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$167.25 USD
-0.02 (-0.01%)
Updated Apr 24, 2024 04:00 PM ET
After-Market: $167.18 -0.07 (-0.04%) 7:46 PM ET
3-Hold of 5 3
D Value A Growth B Momentum B VGM
Zacks News
Bio-Rad (BIO) Faces Soft Industry-wide Demand, Macro Woes
by Zacks Equity Research
Bio-Rad's (BIO) margin performance suffers due to elevated raw material costs, increased logistics costs and higher employee-related expenses.
Venus Concept (VERO) Expands Global Reach With New Partnerships
by Zacks Equity Research
Venus Concept (VERO) expects its deals to fetch continued success in both the United Kingdom and India.
Quest Diagnostics (DGX) Unveils the 88-Compound NPS Test Panel
by Zacks Equity Research
Quest Diagnostics (DGX) launches the new 88-Compound NPS test panel to address the changing drug epidemic.
How to Find the Best Top-Ranked Stocks to Buy in 2024
by Benjamin Rains
Here is how to utilize the Filtered Zacks Rank 5 Stock Screen to help find potentially winning stocks to buy to close out December and throughout 2024.
Here's Why You Should Invest in Penumbra (PEN) Stock Now
by Zacks Equity Research
Investors are optimistic about Penumbra (PEN), which is led by growth in vascular and neuro businesses.
Align's (ALGN) Invisalign Palatal Expander System Gets FDA Nod
by Zacks Equity Research
Align's (ALGN) Invisalign Palatal Expander is the company's first direct 3D-printed orthodontic device. It offers a safe, pleasant and clinically effective alternative to traditional palatal expanders.
CVS Health (CVS) New Opportunities Drive Growth, Macro Woes Stay
by Zacks Equity Research
CVS Health's (CVS) restructuring plan poises it well, along with its strategic buyouts.
SenesTech (SNES) Likely to Expand Into China With New Deal
by Zacks Equity Research
This partnership provides SenesTech (SNES) with a gateway into one of the largest pest control markets globally, with the support and expertise of Fruit Tree.
5 Nasdaq Composite Laggards Likely to Gather Pace in 2024
by Nalak Das
We have narrowed our search to five Nasdaq Composite listed laggards of 2023 with strong potential for 2024. These are: PEP, KHC, WMG, PODD, BGNE.
Charles River's (CRL) Memphis Site Achieves Crucial Approval
by Zacks Equity Research
Charles River (CRL) reaches an important milestone in cell therapy manufacturing collaboration with Vertex Pharmaceuticals.
Here's Why You Should Retain Tandem Diabetes (TNDM) Now
by Zacks Equity Research
Investors remain optimistic about Tandem Diabetes (TNDM), backed by the impressive spree of product introductions.
Abbott (ABT) Gains From Global Expansion Amid Macro Woes
by Zacks Equity Research
Abbott's (ABT) EPD business continues to witness low double-digit growth. It has successfully positioned itself as one of the best-positioned large healthcare companies in emerging markets.
Thermo Fisher (TMO) to Allocate IFA Testing Kits With New Pact
by Zacks Equity Research
Thermo Fisher (TMO) will continue to meet the evolving needs of laboratories and healthcare professionals by expanding its immunology product portfolio of EliA autoimmune diagnostics.
Quest Diagnostics' (DGX) Haystack Oncology Inks New Deal
by Zacks Equity Research
Quest Diagnostics' (DGX) wholly owned subsidiary, Haystack Oncology, partners with the Rutgers Cancer Institute of New Jersey.
Here's Why You Should Invest in IDEXX (IDXX) Stock Right Now
by Zacks Equity Research
Investors continue to be optimistic about IDEXX (IDXX), backed by the strength of the CAG Diagnostics business.
Here's Why You Should Retain Hologic (HOLX) Stock for Now
by Zacks Equity Research
Investors are optimistic about Hologic (HOLX), which is led by growth with recovery in procedural volumes and acceleration from new business lines.
Here's Why You Should Retain Globus Medical (GMED) Stock Now
by Zacks Equity Research
Investors are optimistic about Globus Medical (GMED) on growing demand for musculoskeletal devices and its strong solvency position.
Neogen (NEOG) to Advance Feline DNA Testing With New Pact
by Zacks Equity Research
Neogen's (NEOG) strategic alliance will expand feline DNA testing and strengthen its relationship with the kitty community.
Align's (ALGN) New Launches Aid, Macroeconomic Woes Linger
by Zacks Equity Research
Align Technology (ALGN) performs digital treatment planning and interpretation for restorative cases worldwide, including Costa Rica, China, Germany, Spain, Poland and Japan, among others.
Align Technologies (ALGN) Secures Updated Medical Device License
by Zacks Equity Research
Align Technologies' (ALGN) Invisalign Palatal Expander system receives an updated medical device license from Health Canada.
Here's Why You Should Buy Neogen (NEOG) Stock Now
by Zacks Equity Research
Investors are optimistic about Neogen (NEOG), owing to product launches and the performance of segments.
Tandem Diabetes (TNDM) Avails Tandem Source in the United States
by Zacks Equity Research
Tandem Diabetes (TNDM) announces the full U.S. launch of Tandem Source, a new diabetes management platform for customers and healthcare providers.
Integra (IART) to Advance ENT Division With New Buyout Deal
by Zacks Equity Research
Integra (IART) will be among the top suppliers of ENT products and technologies following the Acclarent acquisition.
Myriad Genetics' (MYGN) New Partnerships Aid Amid FX Woes
by Zacks Equity Research
Myriad Genetics (MYGN) continues to record strong revenue growth from companion diagnostics, including significant revenue share from its proprietary myChoiceCDx test.
Medtronic (MDT) Expands AI-Driven Care With New Partnership
by Zacks Equity Research
Medtronic's (MDT) expanded collaboration with Cosmo Pharmaceuticals is a strategic step forward in its quest to use AI to improve patient care.